Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
Amazon Reviews Supplier Costs as U.S.–China Tariffs Ease 
U.S. Government Invests $1 Billion in L3Harris Rocket Motor Business to Secure Missile Supply Chain 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
U.S. Lawmakers Raise Alarm Over Trump Approval of Nvidia AI Chip Sales to China 
Tesla, EEOC Move Toward Mediation in Racial Harassment Lawsuit 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
AFT Leaves X Over AI-Generated Images of Minors 
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
Coca-Cola Shelves Costa Coffee Sale After Low Private Equity Offers 
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
Chevron Set to Expand Venezuela Operations as U.S. Signals Shift on Oil Sanctions 
BOSTON, April 05, 2017 -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that clinical data from the ongoing Phase 2 study of its lead product candidate A4250 in children with cholestatic liver disease has been selected by the European Association for the Study of the Liver (EASL) for an oral presentation during the late breaker session at The International Liver Congress™ (ILC) 2017 being held April 19-23, 2017, at the RAI Amsterdam in Amsterdam.
Details of the presentation are as follows:
Title: The Ileal Bile Acid Transport inhibitor A4250 decreases pruritus and serum bile acids in cholestatic liver diseases – an ongoing multiple dose, open-label, multicentre study
Session: Late Breaker
Date / Time: Saturday, April 22, 4:45 p.m. – 5:00 p.m. CET
Location: Hall 5
Presenter: Dr. Ulrich Baumann, Professor of Pediatric Gastroenterology and Hepatology at Hannover Medical School, Germany
EASL’s ILC, now in its 52nd year, is a multi-disciplinary scientific Congress which brings more than 10,000 clinicians and scientists together annually to discuss clinical innovation and research. For more information about the conference, visit https://ilc-congress.eu/.
About Albireo
Albireo is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo’s clinical pipeline includes two Phase 2 product candidates and one Phase 3 product candidate. Albireo was spun out from AstraZeneca in 2008.
Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. For more information on Albireo, please visit http://www.albireopharma.com.
Source: Albireo Pharma, Inc.
Investor Contact: Hans Vitzthum LifeSci Advisors, LLC. 212-915-2568 Media Contact: Heather Anderson 6 Degrees 980-938-0260 [email protected]
